Published in PLoS Pathog on January 15, 2010
Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol (2010) 3.77
Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe (2014) 2.00
West Nile virus differentially modulates the unfolded protein response to facilitate replication and immune evasion. J Virol (2010) 1.49
Forty-five years of Marburg virus research. Viruses (2012) 1.34
The Marburg virus VP24 protein interacts with Keap1 to activate the cytoprotective antioxidant response pathway. Cell Rep (2014) 1.29
Interplay between innate immunity and negative-strand RNA viruses: towards a rational model. Microbiol Mol Biol Rev (2011) 1.22
Interferons and viruses: an evolutionary arms race of molecular interactions. Trends Immunol (2015) 1.22
Dengue virus co-opts UBR4 to degrade STAT2 and antagonize type I interferon signaling. PLoS Pathog (2013) 1.20
The ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. PLoS Pathog (2012) 1.20
Structural basis for Marburg virus VP35-mediated immune evasion mechanisms. Proc Natl Acad Sci U S A (2012) 1.18
Marburg virus VP40 antagonizes interferon signaling in a species-specific manner. J Virol (2011) 1.10
Filoviral immune evasion mechanisms. Viruses (2011) 1.10
Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat Rev Microbiol (2015) 1.07
A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon. PLoS One (2011) 1.07
Clinical aspects of Marburg hemorrhagic fever. Future Virol (2011) 1.06
Crystal structure of Marburg virus VP24. J Virol (2014) 1.04
Marburg virus VP35 can both fully coat the backbone and cap the ends of dsRNA for interferon antagonism. PLoS Pathog (2012) 1.03
Evolutionary maintenance of filovirus-like genes in bat genomes. BMC Evol Biol (2011) 1.02
Intracellular events and cell fate in filovirus infection. Viruses (2011) 1.01
The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains. J Virol (2013) 1.00
Characterization of uncultivable bat influenza virus using a replicative synthetic virus. PLoS Pathog (2014) 0.98
Emerging virus diseases: can we ever expect the unexpected? Emerg Microbes Infect (2012) 0.97
In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. J Mol Biol (2014) 0.96
Key genomic changes necessary for an in vivo lethal mouse marburgvirus variant selection process. J Virol (2011) 0.96
Deficient IFN signaling by myeloid cells leads to MAVS-dependent virus-induced sepsis. PLoS Pathog (2014) 0.95
The ebolavirus VP24 interferon antagonist: know your enemy. Virulence (2012) 0.94
Morbillivirus v proteins exhibit multiple mechanisms to block type 1 and type 2 interferon signalling pathways. PLoS One (2013) 0.93
The role of antigen-presenting cells in filoviral hemorrhagic fever: gaps in current knowledge. Antiviral Res (2012) 0.92
Advances in virus-like particle vaccines for filoviruses. J Infect Dis (2011) 0.92
Correlates of immunity to filovirus infection. Viruses (2011) 0.91
Human cytomegalovirus IE1 protein disrupts interleukin-6 signaling by sequestering STAT3 in the nucleus. J Virol (2013) 0.89
Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins. Cell Rep (2016) 0.86
Evasion of IFN-γ signaling by Francisella novicida is dependent upon Francisella outer membrane protein C. PLoS One (2011) 0.86
Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics. Virology (2015) 0.83
Innate immune evasion by filoviruses. Virology (2015) 0.82
The VP40 protein of Marburg virus exhibits impaired budding and increased sensitivity to human tetherin following mouse adaptation. J Virol (2014) 0.82
Immunology of bats and their viruses: challenges and opportunities. Viruses (2014) 0.82
Marburg Virus VP24 Protein Relieves Suppression of the NF-κB Pathway Through Interaction With Kelch-like ECH-Associated Protein 1. J Infect Dis (2015) 0.81
Characterizing alpha helical properties of Ebola viral proteins as potential targets for inhibition of alpha-helix mediated protein-protein interactions. F1000Res (2014) 0.81
Amino Acid Residue at Position 79 of Marburg Virus VP40 Confers Interferon Antagonism in Mouse Cells. J Infect Dis (2015) 0.80
Rodent-Adapted Filoviruses and the Molecular Basis of Pathogenesis. J Mol Biol (2016) 0.79
Immunological features underlying viral hemorrhagic fevers. Curr Opin Immunol (2015) 0.79
Filoviruses: One of These Things is (not) Like the Other. Viruses (2015) 0.78
Crystal Structure of Marburg Virus VP40 Reveals a Broad, Basic Patch for Matrix Assembly and a Requirement of the N-Terminal Domain for Immunosuppression. J Virol (2015) 0.78
A Single Amino Acid Change in the Marburg Virus Matrix Protein VP40 Provides a Replicative Advantage in a Species-Specific Manner. J Virol (2015) 0.78
The many faces of the flavivirus NS5 protein in antagonism of type I interferon signaling. J Virol (2016) 0.78
Effects of Filovirus Interferon Antagonists on Responses of Human Monocyte-Derived Dendritic Cells to RNA Virus Infection. J Virol (2016) 0.77
Molecular Mechanisms of Innate Immune Inhibition by Non-Segmented Negative-Sense RNA Viruses. J Mol Biol (2016) 0.76
Different functions of the common P/V/W and V-specific domains of rinderpest virus V protein in blocking IFN signalling. J Gen Virol (2013) 0.76
The host E3-Ubiquitin ligase TRIM6 ubiquitinates the Ebola virus VP35 protein and promotes virus replication. J Virol (2017) 0.75
Importin-α7 Is Involved in the Formation of Ebola Virus Inclusion Bodies but Is Not Essential for Pathogenicity in Mice. J Infect Dis (2015) 0.75
The Role of Cytokines and Chemokines in Filovirus Infection. Viruses (2015) 0.75
A hamster model for Marburg virus infection accurately recapitulates Marburg hemorrhagic fever. Sci Rep (2016) 0.75
Ebola Virus Does Not Induce Stress Granule Formation during Infection and Sequesters Stress Granule Proteins within Viral Inclusions. J Virol (2016) 0.75
Marburg Virus Reverse Genetics Systems. Viruses (2016) 0.75
Innate Immune Responses of Bat and Human Cells to Filoviruses: Commonalities and Distinctions. J Virol (2017) 0.75
VP24-karyopherin alpha binding affinities differ between Ebolavirus species influencing interferon inhibition and VP24 stability. J Virol (2016) 0.75
Viral Inhibition of the IFN-Induced JAK/STAT Signalling Pathway: Development of Live Attenuated Vaccines by Mutation of Viral-Encoded IFN-Antagonists. Vaccines (Basel) (2016) 0.75
Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses. J Exp Med (2017) 0.75
The Ebola virus VP35 protein binds viral immunostimulatory and host RNAs identified through deep sequencing. PLoS One (2017) 0.75
Immunological Control of Viral Infections in Bats and the Emergence of Viruses Highly Pathogenic to Humans. Front Immunol (2017) 0.75
Molecular pathogenesis of viral hemorrhagic fever. Semin Immunopathol (2017) 0.75
Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene (1991) 38.64
Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol (2005) 11.57
Fruit bats as reservoirs of Ebola virus. Nature (2005) 11.05
HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat Med (2001) 8.38
The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A (1996) 7.02
The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A (2000) 5.46
GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology (1995) 5.34
A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc Natl Acad Sci U S A (2000) 5.30
The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature (1993) 5.24
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73
Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog (2009) 4.56
Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol (2003) 4.45
Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A (2009) 4.38
Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J Virol (1999) 4.32
Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A (1993) 4.23
Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J Virol (2006) 4.01
Inhibition of Lassa and Marburg virus production by tetherin. J Virol (2008) 3.98
Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res (1993) 3.89
Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med (2002) 3.88
Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol (2006) 3.84
Discovery of swine as a host for the Reston ebolavirus. Science (2009) 3.68
Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis (1999) 3.62
Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol (2006) 3.50
NF-kappa B subunit-specific regulation of the interleukin-8 promoter. Mol Cell Biol (1993) 3.27
Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell (1998) 3.25
Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4. J Virol (2003) 3.05
Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol (2004) 2.92
Large serological survey showing cocirculation of Ebola and Marburg viruses in Gabonese bat populations, and a high seroprevalence of both viruses in Rousettus aegyptiacus. BMC Infect Dis (2009) 2.82
The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol Cell (2002) 2.80
Inhibition of Ran guanosine triphosphatase-dependent nuclear transport by the matrix protein of vesicular stomatitis virus. Science (1997) 2.72
Nipah virus V protein evades alpha and gamma interferons by preventing STAT1 and STAT2 activation and nuclear accumulation. J Virol (2002) 2.68
A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. EMBO J (1995) 2.52
Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J Exp Med (1998) 2.49
ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. Proc Natl Acad Sci U S A (2008) 2.48
Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. J Virol (2005) 2.44
Molecular determinants of Ebola virus virulence in mice. PLoS Pathog (2006) 2.44
Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol (2005) 2.27
Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology (2000) 2.21
Nedd4 regulates egress of Ebola virus-like particles from host cells. J Virol (2003) 2.19
Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol (2006) 2.14
Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4. J Mol Biol (2003) 2.11
Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J Virol (2009) 2.10
Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett (2002) 2.06
Vesicular stomatitis virus matrix protein inhibits host cell-directed transcription of target genes in vivo. J Virol (1992) 2.01
ISG15 inhibits Nedd4 ubiquitin E3 activity and enhances the innate antiviral response. J Biol Chem (2008) 1.98
Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. J Virol (2004) 1.98
Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol (2007) 1.97
Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro. Virology (2001) 1.97
The vesicular stomatitis virus matrix protein inhibits transcription from the human beta interferon promoter. J Virol (1997) 1.87
Allosteric inhibition of protein tyrosine phosphatase 1B. Nat Struct Mol Biol (2004) 1.86
Structural characterization and membrane binding properties of the matrix protein VP40 of Ebola virus. J Mol Biol (2000) 1.79
Phosphorylation and activation of the DNA binding activity of purified Stat1 by the Janus protein-tyrosine kinases and the epidermal growth factor receptor. J Biol Chem (1995) 1.72
Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells. J Virol (1999) 1.68
Inhibition of interferon signaling by rabies virus phosphoprotein P: activation-dependent binding of STAT1 and STAT2. J Virol (2006) 1.67
Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein. J Virol (2008) 1.65
Protein tyrosine phosphatases in the JAK/STAT pathway. Front Biosci (2008) 1.63
Assembly and budding of Ebolavirus. PLoS Pathog (2006) 1.62
Infection of naive target cells with virus-like particles: implications for the function of ebola virus VP24. J Virol (2006) 1.61
Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding. J Virol (2003) 1.60
Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol Med Microbiol (2004) 1.58
Ultrastructural organization of recombinant Marburg virus nucleoprotein: comparison with Marburg virus inclusions. J Virol (2000) 1.55
Mutation of YMYL in the Nipah virus matrix protein abrogates budding and alters subcellular localization. J Virol (2006) 1.52
VP24 of Marburg virus influences formation of infectious particles. J Virol (2005) 1.46
Measles virus V protein blocks Jak1-mediated phosphorylation of STAT1 to escape IFN-alpha/beta signaling. Virology (2007) 1.44
Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk Lymphoma (2004) 1.44
Ebola virus matrix protein VP40 uses the COPII transport system for its intracellular transport. Cell Host Microbe (2008) 1.31
Regions in Ebola virus VP24 that are important for nucleocapsid formation. J Infect Dis (2007) 1.19
Filovirus replication and transcription. Future Virol (2007) 1.09
Role for amino acids 212KLR214 of Ebola virus VP40 in assembly and budding. J Virol (2007) 1.08
Interferon alpha activates NF-kappaB in JAK1-deficient cells through a TYK2-dependent pathway. J Biol Chem (2005) 1.01
Vacuolar protein sorting pathway contributes to the release of Marburg virus. J Virol (2008) 0.99
Basolateral budding of Marburg virus: VP40 retargets viral glycoprotein GP to the basolateral surface. J Infect Dis (2007) 0.98
The marburg virus 3' noncoding region structurally and functionally differs from that of ebola virus. J Virol (2009) 0.96
Reduced levels of protein tyrosine phosphatase CD45 protect mice from the lethal effects of Ebola virus infection. Cell Host Microbe (2009) 0.94
Early cytokine responses to viral infections and their roles in shaping endogenous cellular immunity. Adv Exp Med Biol (1998) 0.84
Extracellular matrix changes following renal warm ischemic injury in rats. Transplant Proc (2003) 0.77
Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science (2005) 17.19
Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science (2004) 6.70
Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature (2006) 6.46
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73
A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol (2005) 4.71
Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol (2003) 4.45
Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci U S A (2002) 4.26
Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2004) 4.00
Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol (2006) 3.84
Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol (2006) 3.50
Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature (2008) 3.47
A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J Virol (2003) 3.44
Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog (2010) 3.08
Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus. Proc Natl Acad Sci U S A (2008) 2.72
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep (2008) 2.65
Newcastle disease virus V protein is a determinant of host range restriction. J Virol (2003) 2.61
Processing of genome 5' termini as a strategy of negative-strand RNA viruses to avoid RIG-I-dependent interferon induction. PLoS One (2008) 2.45
Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus. PLoS Pathog (2006) 2.26
Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2002) 2.21
Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol (2006) 2.14
Rapid detection protocol for filoviruses. J Clin Virol (2004) 2.13
Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J Virol (2009) 2.10
Cryo-electron tomography of Marburg virus particles and their morphogenesis within infected cells. PLoS Biol (2011) 2.02
Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol (2010) 2.01
Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. J Virol (2004) 1.98
Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol (2007) 1.97
Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. Cell Host Microbe (2013) 1.97
Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J Virol (2009) 1.94
The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling. J Virol (2010) 1.94
A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol (2011) 1.85
TRIM79α, an interferon-stimulated gene product, restricts tick-borne encephalitis virus replication by degrading the viral RNA polymerase. Cell Host Microbe (2011) 1.84
Functional replacement of the carboxy-terminal two-thirds of the influenza A virus NS1 protein with short heterologous dimerization domains. J Virol (2002) 1.81
Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. J Virol (2010) 1.72
Structure of the Ebola VP35 interferon inhibitory domain. Proc Natl Acad Sci U S A (2009) 1.71
Ebola virus VP30-mediated transcription is regulated by RNA secondary structure formation. J Virol (2002) 1.71
Nuclear localization of the Nipah virus W protein allows for inhibition of both virus- and toll-like receptor 3-triggered signaling pathways. J Virol (2005) 1.69
Epitope-specific human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence. J Immunol (2011) 1.68
Effects of influenza A virus NS1 protein on protein expression: the NS1 protein enhances translation and is not required for shutoff of host protein synthesis. J Virol (2002) 1.63
VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother (2006) 1.63
Homo-oligomerization facilitates the interferon-antagonist activity of the ebolavirus VP35 protein. Virology (2005) 1.63
Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol (2012) 1.59
Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res (2007) 1.53
Mutation of YMYL in the Nipah virus matrix protein abrogates budding and alters subcellular localization. J Virol (2006) 1.52
Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic. J Virol (2009) 1.50
Hemagglutinin-pseudotyped green fluorescent protein-expressing influenza viruses for the detection of influenza virus neutralizing antibodies. J Virol (2009) 1.50
Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci Transl Med (2013) 1.49
Phosphorylation of VP30 impairs ebola virus transcription. J Biol Chem (2002) 1.47
Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J Virol (2009) 1.46
1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J Infect Dis (2012) 1.41
A reconstituted replication and transcription system for Ebola virus Reston and comparison with Ebola virus Zaire. Virology (2005) 1.40
The N- and C-terminal domains of the NS1 protein of influenza B virus can independently inhibit IRF-3 and beta interferon promoter activation. J Virol (2004) 1.39
Capsid protein of eastern equine encephalitis virus inhibits host cell gene expression. J Virol (2007) 1.35
Forty-five years of Marburg virus research. Viruses (2012) 1.34
Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling. J Virol (2009) 1.31
The CHR promoter element controls cell cycle-dependent gene transcription and binds the DREAM and MMB complexes. Nucleic Acids Res (2011) 1.30
Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus. Nat Commun (2010) 1.29
Inclusion bodies are a site of ebolavirus replication. J Virol (2012) 1.29
Ebola virus transcription activator VP30 is a zinc-binding protein. J Virol (2003) 1.29
Discussions and decisions of the 2012–2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012–June 2013. Arch Virol (2014) 1.27
Oligomerization of Ebola virus VP30 is essential for viral transcription and can be inhibited by a synthetic peptide. J Biol Chem (2003) 1.24
Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses. J Virol (2012) 1.20
Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses. PLoS Pathog (2012) 1.19
Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain. Virology (2007) 1.19
Nipah virus sequesters inactive STAT1 in the nucleus via a P gene-encoded mechanism. J Virol (2009) 1.18
Structural basis for Marburg virus VP35-mediated immune evasion mechanisms. Proc Natl Acad Sci U S A (2012) 1.18
Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol Ther (2008) 1.16
Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition. Cell Microbiol (2009) 1.16
Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol (2013) 1.16
Rescue of recombinant Marburg virus from cDNA is dependent on nucleocapsid protein VP30. J Virol (2006) 1.15
The Ebola virus genomic replication promoter is bipartite and follows the rule of six. J Virol (2005) 1.14
Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells. Immunol Cell Biol (2011) 1.14
Neutralizing anti-influenza virus monoclonal antibodies: therapeutics and tools for discovery. Int Rev Immunol (2009) 1.13
An upstream open reading frame modulates ebola virus polymerase translation and virus replication. PLoS Pathog (2013) 1.12
Chimeric influenza A viruses with a functional influenza B virus neuraminidase or hemagglutinin. J Virol (2003) 1.12
Identification of phosphorylation-dependent interaction partners of the adapter protein ADAP using quantitative mass spectrometry: SILAC vs (18)O-labeling. J Proteome Res (2010) 1.12
Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions. Antimicrob Agents Chemother (2011) 1.11
Marburg virus VP40 antagonizes interferon signaling in a species-specific manner. J Virol (2011) 1.10
Filoviral immune evasion mechanisms. Viruses (2011) 1.10
Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol (2013) 1.10
Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function. J Virol (2010) 1.07
Proactive office encounter: a systematic approach to preventive and chronic care at every patient encounter. Perm J (2010) 1.06
Severe acute respiratory syndrome coronavirus triggers apoptosis via protein kinase R but is resistant to its antiviral activity. J Virol (2008) 1.06
Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain. J Mol Biol (2010) 1.04
Ebolavirus VP35 is a multifunctional virulence factor. Virulence (2010) 1.02
Intracellular events and cell fate in filovirus infection. Viruses (2011) 1.01
IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs. Oncogene (2004) 1.01
The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein. J Clin Virol (2004) 1.01
Nipah virus edits its P gene at high frequency to express the V and W proteins. J Virol (2009) 1.00
Identification of residues critical for the interferon antagonist function of Langat virus NS5 reveals a role for the RNA-dependent RNA polymerase domain. J Virol (2007) 1.00
Antagonism of type I interferon responses by new world hantaviruses. J Virol (2010) 1.00